Baseline characteristics | DAPSA LDA+REM | MDA | ||
Variables, n (%) unless otherwise specified | With sustained response (N=396) | Without sustained response (N=112) | With sustained response (N=278) | Without sustained response (N=266) |
Age, mean (SD), years | 46.9 (12.4) | 53.0 (11.2) | 45.5 (12.1) | 51.2 (11.7) |
Male | 225 (56.8) | 48 (42.9) | 166 (59.7) | 123 (46.2) |
BMI, mean (SD), kg/m2 | 28.2 (5.6) | 31.0 (7.1)* | 27.7 (4.9) | 29.9 (6.9) |
Smoking—yes | 73 (18.4) | 18 (16.1) | 55 (19.8) | 44 (16.5) |
Time since first diagnosis of PsA, mean (SD), years | 6.3 (6.9) | 8.0 (8.0) | 5.8 (6.8) | 7.3 (7.4) |
Biologic-naïve patients | 318 (80.3) | 61 (54.5) | 229 (82.4) | 178 (66.9) |
Methotrexate use at randomisation | 216 (54.5) | 60 (53.6) | 146 (52.5) | 144 (54.1) |
Systemic glucocorticoid use at randomisation | 53 (13.4) | 25 (22.3) | 38 (13.7) | 49 (18.4) |
CRP ≥10 mg/dL | 96 (24.2) | 36 (32.1) | 69 (24.8) | 71 (26.7) |
Patients with specific disease characteristics | ||||
TJC (78 joints), mean (SD) | 17.8 (13.2) | 29.2 (18.8) | 16.1 (12.4) | 25.4 (17.3) |
SJC (76 joints), mean (SD) | 10.7 (8.7) | 14.1 (12.4) | 10.2 (7.7) | 12.5 (11.2) |
HAQ-DI score, mean (SD) | 1.1 (0.6) | 1.6 (0.6) | 1.0 (0.6) | 1.5 (0.6) |
PsA pain (VAS 0–100 mm), mean (SD) | 52.5 (24.1) | 61.9 (22.5) | 50.3 (25.0) | 59.1 (21.6) |
Patients’ global assessment (VAS 0–100 mm), mean (SD) | 53.3 (22.9) | 57.8 (24.4) | 51.7 (23.6) | 57.5 (22.4) |
Physician’s global assessment (VAS 0–100 mm), mean (SD) | 55.9 (19.1) | 59.3 (18.7) | 54.4 (19.4) | 58.7 (18.1) |
Presence of enthesitis | 221 (55.8) | 87 (77.7) | 147 (52.9) | 184 (69.2) |
Presence of dactylitis | 155 (39.1) | 50 (44.6) | 116 (41.7) | 97 (36.5) |
Psoriasis affecting ≥3% of BSA | 223 (56.3) | 51 (45.5) | 159 (57.2) | 137 (51.5) |
Psoriasis of nail | 259 (65.4) | 70 (62.5) | 185 (66.5) | 171 (64.3) |
*Data for one patient was missing. Patients having DAPSA assessment at weeks 24 and 104: SEC 150 mg LD, N=167; SEC 150 mg NL, N=162; SEC 300 mg, N=179. Patients having MDA assessment at weeks 24 and 104: SEC 150 mg LD, N=184; SEC 150 mg NL, N=169; SEC 300 mg, N=191.
BMI, body mass index; BSA, body surface area; CRP, C reactive protein; DAPSA, Disease Activity index in Psoriatic Arthritis; HAQ-DI, Health Assessment Questionnaire Disability Index; LD, loading dose; LDA, low disease activity; MDA, minimal disease activity; n, number of evaluable patients; N, number of patients with DAPSA and MDA assessments at weeks 24 and 104 ; NL, without loading dose; PsA, psoriatic arthritis; SEC, secukinumab; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.